The profile of urinary lipid metabolites in cats with bacterial cystitis

#Yui Kobayashi¹, #Tatsuro Nakamura¹, Tomohiro Yonezawa², Koji Kobayashi¹, Takahisa Murata¹

¹ Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.

² Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.

# The authors are equally contributed.

*Corresponding author:

Takahisa Murata.

Department of Animal Radiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.

Telephone: +81-3-5841-7247

E-mail: amurata@mail.ecc.u-tokyo.ac.jp

Running head: URINARY LIPID PROFILE IN CAT CYSTITIS
ABSTRACT

Bacterial cystitis is one of the feline lower urinary tract diseases (FLUTDs). Polyunsaturated fatty acids, such as arachidonic acid (ARA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), are oxidized into various lipid mediators that modulate inflammation. Since the profile of lipid metabolites excreted in urine is useful for assessing inflammatory body conditions, we analyzed 126 types of urinary lipid metabolites in cats with bacterial cystitis. Using LC-MS/MS, we found that the levels of 11 metabolites were higher in the urine of cystitis cats than in the urine of healthy cats. In detail, the urinary levels of ARA, EPA, and DHA and eight of their metabolites were increased in cystitis cats. Focusing on the lipid oxidation pathway, the urinary levels of four cyclooxygenase-, three lipoxygenase-, and one cytochrome p450-dependent oxidated metabolites were increased in bacterial cystitis. These urinary lipid profiles can provide some insight into the pathology and future diagnosis of bacterial cystitis.

KEY WORDS: cat, cystitis, lipid metabolite, urine
Lipid mediators, such as prostaglandins (PGs) and leukotrienes, are crucial molecules that regulate inflammation. Since lipid mediators and their related metabolites are excreted mostly in the urine, their excretion profile can be indicative of the host pathophysiological condition.

Cats have a unique lipid metabolism. They have a limited delta 6 desaturase activity, which converts linoleic acid (LA) to arachidonic acid (ARA), the substrates of lipid mediators [3]. Therefore, cats need to consume ARA from their diet. They also have limited activity of lipoxygenase (LOX) and cytochrome P450 (CYP), which oxidize LA or ARA and produce several types of lipid mediators [11, 12]. We previously found that ARA-derived cyclooxygenase (COX)-metabolites are mainly composed of the urinary metabolite profiles of lipid mediators in healthy cats [7]. However, it remains unknown whether inflammation changes the urinary lipid profile in cats.

Cat is susceptible to urinary diseases, such as urolithiasis and cystitis, because they excrete highly concentrated urine through the short urinary tract. It is estimated that bladder inflammation directly reflects changes in the lipid excretion profile into the urine. Based on this background, we simultaneously analyzed lipid metabolites in cat urine samples with bacterial cystitis.

Urine samples were collected from 10 cats through cystocentesis or catheter from June 2019 to July 2020 at Pigeon Animal Hospital, Tokyo, Koyama Animal Hospital, Tochigi and Veterinary Medical Center, The University of Tokyo, Tokyo. We used residual urine samples which collected for general medical purpose by veterinarians. Sample information is presented in Table 1. Six cats (five castrated males and one spayed female, 4.8±0.9 years old) recruited in this study were diagnosed as healthy based on the results of the biochemical blood test, complete blood count test, and physical condition. These cats had no underlying diseases or intake of medications during the urine collection. Four cats (two castrated males and two uncastrated male, 3.3±0.8 years old) were diagnosed with bacterial cystitis by urine slag test and gram staining following the International Society for Companion Animal Infectious Diseases (ISCAID) guidelines [17]. The urine samples were stored at -28 °C for 3–11 months. Informed written consent was obtained from all the owners at admission.

After the urine samples were centrifuged at 20,000 × g for 5 min, 200 μl of supernatant was mixed with 350 μl 0.1% formic acid water and 50 μl internal standard solution (Table 2). The mixed solutions were applied to a solid-phase extraction cartridge (OASIS µElution plate, Waters, MA,
USA) preconditioned with 200 μl methanol and distilled water (DW). After washing with 200 μl DW and 200 μl hexane, the lipid fractions were eluted with 100 μl methanol. The 5 μl sample solution was injected into a high-performance liquid chromatograph (Nexera 2, Shimadzu, Kyoto, Japan) equipped with a mass spectrometer (LCMS-8060, Shimadzu). Three types of polyunsaturated fatty acids (PUFAs) (ARA, EPA, and DHA), 123 types of metabolites, and 15 types of internal standards (Table 2) were measured and analyzed using the Method Package for Lipid Mediators Version 2 with LabSolutions software (Shimadzu). Each metabolite was identified by the retention time and selected reaction-monitoring ion transition. The change in each metabolite level between healthy and bacterial cystitis urine samples was assessed by comparing the peak area ratio calculated using the following formula: Peak area of each metabolite/peak area of internal standard. Each value was further corrected using the creatinine concentration measured using LabAssay™ Creatinine (Wako, Osaka, Japan). All data are shown as mean ± SEM. Statistical differences were determined by the Mann-Whitney U test for two-group comparisons. Statistical significance was at p-value < 0.05.

In the present analysis, we focused on the lipid metabolites detected in all urine samples of either healthy or cystitis cats. Three PUFAs and 28 types of lipid metabolites were detected in cat urine samples. The detection rates of these lipid metabolites were similar between the healthy and cystitis cats (Table 3). In the current study, there were no PUFAs or lipid metabolites that were detected only in cystitis urine.

Next, we compared the levels of PUFAs and lipid metabolites in urine between healthy subjects and those with cystitis. First, we compared the levels of the three substrates, ARA, EPA, and DHA. As shown in Fig. 1, the levels of the three substrates were increased in cystitis urine compared to healthy ones. Epithelial and immune cells contain large amounts of PUFAs in the cell membrane. Bacterial infections cause the urinary bladder epithelium to abrade and induce leucocyte infiltration into the urinary bladder [6]. The excreted PUFAs in cystitis urine might be derived from the inflamed host epithelium and immune cells.

Fig. 2 shows the ARA metabolites. In 15 types of ARA-COX metabolites detected in all the healthy or cystitis urine samples, the levels of three metabolites were increased and one metabolite (PGK₂) was decreased in cystitis urine. Although the urinary levels of major inflammatory mediators,
PGE2, PGF2α, PGD2, or PGI2 did not change in cystitis, the level of PGI2 metabolites, 6-keto-PGF2α and 6,15-diketo-13,14-dihydro-PGF2α and that of PGE2 metabolite, PGB2, were increased in the urine of cystitis cat. These changes seem to reflect bladder inflammation. Two cystitis cats represented elevated serum creatinine level suggesting decreased renal function (Table 1). We cannot exclude a possibility that decreased renal function also somehow affects the urinary levels of these metabolites.

In four metabolites changed in cystitis urine, PGB2 is a non-enzymatic dehydration product of PGE2 in the presence of a strong base [13]. Urine pH increases to an alkaline pH (7.5–9) when urease-positive bacteria, such as Staphylococcus or Proteus, infected the cat [5, 10]. Thus, there is a possibility that the bacterial infection increased the urine pH to alkaline, which resulted in PGE2 conversion into PGB2. In contrast, the level of another PGE2 metabolite, PGK2, was decreased in the cystitis urine samples. The metabolic pathways of PGK2 remain unclear. Further investigation is required to reveal the mechanism by which the level of PGK2 is decreased in cystitis urine.

CYP2C and CYP2J convert ARA to several types of eicosatrienoic acids (EETs), such as 14, 15-eicosatrienoic acids. Epoxide hydrolase (EH) metabolizes EETs to DHET [14, 16]. Some types of DHET ratioisomers including 14, 15-DHET were detected in rat and human urine [9, 18]. In contrast, we found in the present study that 14,15-DHET was the only ARA-CYP metabolite detected in the urine of cats (Fig. 2B). Lautz et al. have shown that cats express relatively lower levels of CYP2C mRNA than humans and rats [8]. Thus, the lower expression and activity of CYP in cats might result in only 14,15-DHET detection in urine. Conversely, the levels of 14, 15-DHET were increased in the urine of cystitis cats. Interestingly, commensal bacteria have been reported to have EH and produce lipid mediators in the host [2]. Some infected bacteria may be involved in the increased production of 14, 15-DHET in the cat bladder.

In addition to the metabolites of ARA, we found that LA metabolites were also increased in the urine of patients with cystitis. LA is the dominant fatty acid, accounting for 40% of the total fatty acids in cat serum [4]. The levels of other PUFAs, EPA, and DHA were increased in cystitis urine, but the urinary levels of their metabolites did not change. LA and ARA may be consumed mainly in cats with bacterial cystitis. In particular, LOX metabolites of LA were significantly increased in cystitis.
Inflammatory stimulation enhances LOX expression and activity in various cell types [1, 15]. These phenomena may result in an increase in LA-LOX metabolites in cystitis urine.

In summary, we revealed that bacterial cystitis caused an increase in three types of PUFAs, the metabolites of PGE₂, PGI₂, and LA metabolites in the urine of cats. Our findings may help reveal the mechanism of bacterial cystitis and develop a new biomarker for this disease.
POTENTIAL CONFLICTS OF INTEREST

The authors have no conflicts of interest directly relevant to the content of this article.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid from the Japan Society for the Promotion of Science; the Nipponham Foundation, Kobayashi Foundation, Shimadzu Science Foundation. We thank Gentaro Matsukura D.V.M. in Yokodai Pet Clinic, Japan, and Daigo Aoshima D.V.M. in Daigo Pet Clinic, Japan for technical supports.
REFERENCES

1. Ackermann, J. A., Hofheinz, K., Zaiss, M. M. and Krönke, G. 2017. The double-edged role of 12/15-lipoxygenase during inflammation and immunity. *Biochimica et Biophysica Acta* 1862: 371-381.

2. Archelas, A., Iacazio, G. and Kotik, M. 2016. Epoxide Hydrolases and their Application in Organic Synthesis. *Green Biocatalysis*, John Wiley & Sons, Inc., Hoboken, 179-229.

3. Chamberlin, A. J. and Bauer, J. E. 2014. Dietary gamma-linolenic acid supports arachidonic acid accretion and associated Δ-5 desaturase activity in feline uterine but not ovarian tissues. *J. Nutr. Sci.* 3: e43.

4. Fujiwara, M., Mori, N., Sato, T., Tazaki, H., Ishikawa, S., Yamamoto, I. and Arai, T. 2015. Changes in fatty acid composition in tissue and serum of obese cats fed a high fat diet. *BMC Vet. Res* 11: 200.

5. Gatermann, S. and Marre, R. 1989. Cloning and expression of *Staphylococcus* saprophyticus urease gene sequences in *Staphylococcus carnosus* and contribution of the enzyme to virulence. *Infect. Immun.* 57: 2998–3002.

6. Homma, Y ., Akiyama, Y ., Tomoe, H., Furuta, A., Ueda, T., Maeda, D., Lin, A. T. L., Kuo, H. C., Lee, M. H., Oh, S. J., Kim, J. C. and Lee, K. S. 2020. Clinical guidelines for interstitial cystitis/bladder pain syndrome. *Int. J. Urol.* 27: 578-589.

7. Kobayashi, Y ., Nakamura, T., Kobayashi, K. and Murata, T. 2020. The profile of urinary lipid metabolites in cats. *J. Vet. Med. Sci.* 82(7): 1017–1020.

8. Lautz, L. S., Jeddi, M. Z., Girolami, F., Nebbia, C. and Dorne, J. L. C. M. 2021. Metabolism and pharmacokinetics of pharmaceuticals in cats (Felix sylvestris catus) and implications for the risk assessment of feed additives and contaminants. *Toxicol. Lett.* 338: 114-127.

9. Mota-Zamorano, S., Robles, N. R., Lopez-Gomez, J., Cancho, B., González, L. M., Garcia-Pino, G., Navarro-Pérez, M. L. and Gervasini, G. 2021. Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease. *EXCLI J.* 20: 698-708.

10. Nicholson, E. B., Concaugh, E. A., Foxall, P. A., Island, M. D. and Mobley, H. L. T. 1993. *Proteus mirabilis* urease: Transcriptional regulation by UreR. *J. Bacteriol.* 175: 465-473.
11. Okamatsu, G., Kawakami, K., Komatsu, T., Kitazawa, T., Uno, Y. and Teraoka, H. 2017. Functional expression and comparative characterization of four feline P450 cytochromes using fluorescent substrates. *Xenobiotica*. 47(11): 951-961.

12. Ono, Y., Sugiyama, S., Matsushita, M., Kitazawa, T., Amano, T., Uno, Y., Ikushiro, S. and Teraoka, H. 2019. Limited expression of functional cytochrome p450 2c subtypes in the liver and small intestine of domestic cats. *Xenobiotica*. 49: 627–635.

13. Perera, S. K. and Fedor, L. R. 1979. Acid-and Base-Catalyzed Dehydration of Prostaglandin E2 to Prostaglandin A2 and General-Base-Catalyzed Isomerization of Prostaglandin A2 to Prostaglandin B2. *J. Am. Chem. Soc.* 101, 24: 7390-7393.

14. Spector, A. A., Fang, X., Snyder, G. D. and Weintraub, N. L. 2004. Epoxyeicosatrienoic acids (EETs Metabolism and biochemical function. *Progress in lipid research* 43: 55-90.

15. Sun, Q.-Y., Zhou, H.-H. and Mao, X.-Y. 2019. Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death. *Oxid. Med. Cell Longev*. 2019: 2749173.

16. Tacconelli, S. and Patrignani, P. 2014. Inside epoxyeicosatrienoic acids and cardiovascular disease. *Front Pharmacol*. doi:10.3389/fphar.2014.00239.

17. Weese, J. S., Blondeau, J., Boothe, D., Guardabassi, L. G., Gumley, N., Papich, M., Jessen, L. R., Lappin, M., Rankin, S., Westropp, J. L. and Sykes, J. 2019. International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. *Vet. J.* 247: 8-25.

18. Yu, Z., Xu, F., Huse, L. M., Morisseau, C., Draper, A. J., Newman, J. W., Parker, C., Graham, L. R., Engler, M. M., Hammock, B. D., Zeldin, D. C. and Kroetz, D. L. 2000. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circ. Res.* 87: 992–998.
**Figure legends**

**Figure 1** The amounts of polyunsaturated fatty acids (PUFAs) detected in urine of cats.

The amounts of arachidonic acid (ARA) (A), eicosapentaenoic acid (EPA) (B) and docosahexaenoic acid (DHA) (C) detected in urine of healthy (HS) or bacterial cystitis (Cys) cats. A circle means the ratio of polyunsaturated fatty acids (PUFAs) detected in each cat. Black bar means average ratio of each group. IS: internal standard. **: p<0.01 compared with healthy and bacterial cystitis.

**Figure 2** Metabolites of arachidonic acid (ARA).

Metabolites of arachidonic acid (ARA) detected in urine of healthy (HS) and bacterial cystitis (Cys) cats. A circle means the ratio of lipid metabolites detected in each cat. Black bar means average ratio of each group. COX: cyclooxygenase, CYP: cytochrome p450, DHET: dihydroxyeicosatrienoic acid, EET: eicosatrienoic acid, HETE: Hydroxyeicosatetraenoic acid, PG: prostaglandin, IS: internal standard. *: p<0.05, **: p<0.01 compared with healthy and bacterial cystitis.

**Figure 3** Metabolites of linoleic acid (LA).

Metabolites of linoleic acid (LA) detected in urine of healthy (HS) and bacterial cystitis (Cys) cats. A circle means the ratio of lipid metabolites detected in each cat. Black bar means average ratio of each group. CYP: cytochrome p450, DiHOME: dihydroxy-octadecenoic acid, HODE: Hydroxyoctadecadienoic acid, KODE: keto-octadecadienoic acid, LOX: lipoxygenase, PG: prostaglandin, IS: internal standard. *: p<0.05, compared with healthy and bacterial cystitis.
Table 1. Gender clinical and the results of signs, blood test and urine test

| Number | Institution | Gender | Fix  | Collecting Method | Age (year) | TP (g/dl) | ALT (U/l) | Cre (mg/dl) | WBC (10^5/μl) | HCT (%) | pH |
|--------|-------------|--------|------|-------------------|------------|----------|----------|------------|--------------|---------|----|
| Healthy |             |        |      |                   |            |          |          |            |              |         |    |
| 1      | Pigeon      | M      | C    | cystocentesis     | 2          | 7.5      | 50       | 0.96       | 82           | 36.1    | 6.70 |
| 2      | Pigeon      | M      | C    | cystocentesis     | 3          | 7.3      | 39       | 1.34       | 176          | 37.1    | 7.09 |
| 3      | Pigeon      | M      | C    | cystocentesis     | 8          | 6.7      | 41       | 1.7        | 71           | 44.3    | 6.12 |
| 4      | Pigeon      | F      | S    | cystocentesis     | 4          | 6.5      | 54       | 1.62       | 91           | 48.3    | 6.64 |
| 5      | VMCUT       | M      | C    | cystocentesis     | 6          | 5.5      | 14       | 0.81       | 115          | -       | 6.80 |
| 6      | VMCUT       | M      | C    | catheter          | 6          | 7.0      | 57       | 1.22       | 100          | -       | 9.13 |
| Cystitis |             |        |      |                   |            |          |          |            |              |         |    |
| 1      | Koyama      | M      | -    | catheter          | 2          | -        | -        | -          | -            | -       | 7.67 |
| 2      | Koyama      | M      | C    | catheter          | 4          | 7.2      | -        | -          | -            | -       | 7.14 |
| 3      | Koyama      | M      | -    | catheter          | 2          | 7.0      | -        | 2.47       | -            | -       | 7.80 |
| 4      | Koyama      | M      | C    | catheter          | 5          | 8.2      | -        | 5.28       | -            | -       | 7.12 |

*Pigeon; Pigeon animal hospital, VMCUT; Veterinary Medical Center, The University of Tokyo
Koyama; Koyama Animal Hospital
M; Male, F; Female, C, Castrated Male; S, Spayed Female
TP, Total Protein; ALT, Alanine Transaminase
Cre, Serum Creatinin; WBC, White Blood Cell; HCT, Hematocrit; pH, pH of urine
Table 2. The list of internal standards (IS)

| Name                                              | Concentration (ng/mL) |
|---------------------------------------------------|-----------------------|
| tetranor-PGEM-d6                                  | 25.0                  |
| 6-keto-Prostaglandin F1α-d4                       | 25.0                  |
| Thromboxane B2-d4 (TXB2-d4)                       | 25.0                  |
| Prostaglandin F2α-d4 (PGF2α-d4)                   | 25.0                  |
| Prostaglandin E2-d4 (PGE2-d4)                     | 25.0                  |
| Prostaglandin D2-d4 (PGD2-d4)                     | 25.0                  |
| Leukotriene C4-d5 (LTC4-d4)                       | 25.0                  |
| Leukotriene B4-d4 (LTB4-d4)                       | 25.0                  |
| 5(S) HETE-d8                                      | 25.0                  |
| 12(S) HETE-d8                                     | 25.0                  |
| 15(S) HETE-d8                                     | 25.0                  |
| Oleoyl Ethanolamide-d4 (OEA-d4)                   | 0.5                   |
| Eicosapentaenoic Acid-d5 (EPA-d5)                 | 500.0                 |
| Docosahexaenoic Acid-d5 (DHA-d5)                  | 50.0                  |
| Arachidonic Acid-d8 (ARA-d8)                      | 500.0                 |
| PUFA | enzyme | Name                                                      | Detection rate (%) |                |
|------|--------|-----------------------------------------------------------|--------------------|----------------|
|      |        |                                                           | Healthy           | cystitis       |
| LA   | LOX    | 9-ODE                                                    | 83.3              | 100.0          |
|      |        | 9-KODE                                                   | 66.7              | 100.0          |
|      |        | 13-ODE                                                   | 83.3              | 100.0          |
| CYP  | 9,10-DiHOM       | E                                      | 100.0              | 100.0          |
|      |        | 12,13-DiHOM                                               | 100.0              | 100.0          |
| AA   |        | Arachidonic Acid (AA)                                    | 100.0              | 100.0          |
| COX  |        | 11-dehydro-Thromboxane B2 (TXB2)                         | 100.0              | 100.0          |
|      |        | 11-HETE                                                  | 50.0               | 100.0          |
|      |        | 13,14-dihydro-15-keto-tetranor-Prostaglandin D2 (PGD2)   | 100.0              | 50.0           |
|      |        | 13,14-dihydro-15-keto-tetranor-Prostaglandin E2 (PGE2)   | 100.0              | 100.0          |
|      |        | 13,14-dihydro-15-keto-tetranor-PGF1b                     | 100.0              | 100.0          |
|      |        | 6-keto-Prostaglandin F1a (PGF1a)                         | 100.0              | 100.0          |
|      |        | 6,15-diketo-13,14-dihydro-PGF1a                          | 100.0              | 100.0          |
|      |        | Prostaglandin A2 (PGA2)                                  | 100.0              | 100.0          |
|      |        | Prostaglandin B2 (PGB2)                                 | 50.0               | 100.0          |
|      |        | Prostaglandin D2 (PGD2)                                 | 100.0              | 100.0          |
|      |        | Prostaglandin E2 (PGE2)                                 | 100.0              | 100.0          |
|      |        | Prostaglandin F2a (PGF2a)                               | 100.0              | 100.0          |
|      |        | Prostaglandin J2 (PGJ2)                                 | 100.0              | 100.0          |
|      |        | Prostaglandin K2 (PGK2)                                 | 100.0              | 75.0           |
|      |        | tetranor-PGEM                                            | 100.0              | 100.0          |
| CYP  | 14,15-DHET | E                                      | 33.3               | 100.0          |
| non-OX |        | 2,3-dinor-8-iso-PGF2a                                    | 100.0              | 100.0          |
|      |        | 5-ipF2a-VI                                               | 100.0              | 100.0          |
|      |        | 8-iso-15(R)-PGF2a                                       | 100.0              | 100.0          |
|      |        | 8-iso-PGF2a                                              | 100.0              | 100.0          |
| DHA  |        | Docosahexaenoic Acid (DHA)                               | 100.0              | 100.0          |
|      |        | Eicosapentaenoic Acid (EPA)                             | 100.0              | 100.0          |
| EPA  |        | PGE3                                                     | 100.0              | 100.0          |
|      |        | PGD3                                                     | 100.0              | 100.0          |
| LOX  |        | 17,18-DiHET                                              | 83.3               | 100.0          |
Fig. 1

|   | ARA |   | EPA |   | DHA |
|---|-----|---|-----|---|-----|
| A |     |   |     |   |     |
| B | ** |   | ** |   |     |
| C |     |   |     | **|     |

Ratio to IS

|       | ARA |   | EPA |   | DHA |
|-------|-----|---|-----|---|-----|
| HS Cys|     |   |     |   |     |
Fig. 3

A 9-KODE  B 9-HODE  C 13-HODE  D 9,10-DiHOME  E 12,13-DiHOME

Ratio to IS (×10^2)

HS Cys

Ratio to IS (×10^-1)

HS Cys

Ratio to IS (×10^-1)

HS Cys

Ratio to IS

HS Cys

Ratio to IS

HS Cys

p=0.067

p=0.067